BACKGROUND: Statins are effective in reducing events from coronary heart disease and can prolong survival. However, this benefit is controversial when other concurrent serious health problems greatly limit the patient's longevity. METHODS: We conducted a retrospective chart review of patients with advanced lung cancer who were receiving statins and had lived for at least one month since diagnosis. FINDINGS: Forty-seven patients with median age of 71 years were included. Discontinuation of statins occurred in 25 patients (53.2%) before the date of death. Median survival was 370 days. Statins were discontinued at a median of 244 days after cancer diagnosis. Discontinuations were more prevalent in patients who received chemotherapy or had a history of cerebrovascular diseases. Lipid monitoring was observed in 25 patients (53.2%). INTERPRETATION: About half of patients with advanced lung cancer who were prescribed statins did not have this drug discontinued until the time of death. Lipid monitoring was suboptimal and, when it occurred, indicated the lipid goal was rarely achieved.
BACKGROUND: Statins are effective in reducing events from coronary heart disease and can prolong survival. However, this benefit is controversial when other concurrent serious health problems greatly limit the patient's longevity. METHODS: We conducted a retrospective chart review of patients with advanced lung cancer who were receiving statins and had lived for at least one month since diagnosis. FINDINGS: Forty-seven patients with median age of 71 years were included. Discontinuation of statins occurred in 25 patients (53.2%) before the date of death. Median survival was 370 days. Statins were discontinued at a median of 244 days after cancer diagnosis. Discontinuations were more prevalent in patients who received chemotherapy or had a history of cerebrovascular diseases. Lipid monitoring was observed in 25 patients (53.2%). INTERPRETATION: About half of patients with advanced lung cancer who were prescribed statins did not have this drug discontinued until the time of death. Lipid monitoring was suboptimal and, when it occurred, indicated the lipid goal was rarely achieved.
Authors: Jennifer Tjia; Sarah L Cutrona; Daniel Peterson; George Reed; Susan E Andrade; Susan L Mitchell Journal: J Am Geriatr Soc Date: 2014-11-04 Impact factor: 5.562
Authors: Elizabeth A Bayliss; Michael R Bronsert; Liza M Reifler; Jennifer L Ellis; John F Steiner; Deanna B McQuillen; Diane L Fairclough Journal: J Palliat Med Date: 2013-01-10 Impact factor: 2.947
Authors: Milly A van der Ploeg; Sven Streit; Wilco P Achterberg; Erna Beers; Arthur M Bohnen; Robert A Burman; Claire Collins; Fabio G Franco; Biljana Gerasimovska-Kitanovska; Sandra Gintere; Raquel Gomez Bravo; Kathryn Hoffmann; Claudia Iftode; Sanda Kreitmayer Peštić; Tuomas H Koskela; Donata Kurpas; Hubert Maisonneuve; Christan D Mallen; Christoph Merlo; Yolanda Mueller; Christiane Muth; Ferdinando Petrazzuoli; Nicolas Rodondi; Thomas Rosemann; Martin Sattler; Tjard Schermer; Marija Petek Šter; Zuzana Švadlenková; Athina Tatsioni; Hans Thulesius; Victoria Tkachenko; Péter Torzsa; Rosy Tsopra; Canan Tuz; Bert Vaes; Rita P A Viegas; Shlomo Vinker; Katharine A Wallis; Andreas Zeller; Jacobijn Gussekloo; Rosalinde K E Poortvliet Journal: J Gen Intern Med Date: 2019-01-16 Impact factor: 5.128